BingX Academy 2.0 Launches to Empower Global Learners in Web3 and Crypto

BingX Academy 2.0 Launches to Empower Global Learners in Web3 and Crypto

PANAMA CITY, Oct. 20, 2025 /PRNewswire/ -- BingX, a leading cryptocurrency exchange and Web3 AI company, today announced a major upgrade to BingX Academy, introducing a more intuitive interface, expanded resources, and interactive learning features...

HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025

HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025

Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ --...

2025 OMODA&JAECOO International User Summit Charts a New Chapter as AIMOGA Unveils Brand-New Global Strategy

2025 OMODA&JAECOO International User Summit Charts a New Chapter as AIMOGA Unveils Brand-New Global Strategy

KUALA LUMPUR, Malaysia and WUHU, China, Oct. 20, 2025 /PRNewswire/ -- On October 19, the 2025 AIMOGA Global Launch was held in Wuhu, marking a milestone moment as AIMOGA—incubated by the parent company of OMODA&JAECOO—officially unveiled its new...

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). OS was significantly...

HD Hyundai Vice Chairman Chung Kisun Promoted to Chairman

HD Hyundai Vice Chairman Chung Kisun Promoted to Chairman

SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- HD Hyundai announced that Executive Vice Chairman Chung Kisun has been promoted to Chairman in its latest executive appointments. Chung Kisun, HD Hyundai Chairman Chairman Chung holds a bachelor's...

From Corporate Social Responsibility To Global Consensus: Chery's "Ride Green Life" Unites the World for a Sustainable Future

From Corporate Social Responsibility To Global Consensus: Chery's "Ride Green Life" Unites the World for a Sustainable Future

WUHU, China, Oct. 20, 2025 /PRNewswire/ -- As the global automotive industry accelerates toward a green, low-carbon future, corporate social responsibility has evolved — now defined by sustainable practices fostering harmony between people, society,...

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions

LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances...

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate...

Zeekr Group to Report Third Quarter 2025 Financial Results on November 17, 2025

Zeekr Group to Report Third Quarter 2025 Financial Results on November 17, 2025

HANGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced that it will report its unaudited...

  • 1
  • ...
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • ...
  • 271
  • menu
    menu